News | March 12, 2025
Nectar Lifesciences receives 7 observations from EDQM for API facility
The European regulator will conduct a re-inspection of the facility to verify the compliance
The European regulator will conduct a re-inspection of the facility to verify the compliance
The company will provide the necessary response on these observations to USFDA within stipulated 15 days
This is Senores' second API manufacturing facility adding significantly to the existing API manufacturing capabilities.
The observations issued are neither repeated observations nor related to data integrity
The Alathur facility specializes in the production of Cephalosporin antibiotics
Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis
Olanzapine is indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders
The company has paid an Interim Environmental Damage Compensation of Rs. 3.40 lakh to GPCB
The company ensures a reliable and strong portfolio at competitive prices without compromising on excellent quality
Subscribe To Our Newsletter & Stay Updated
